Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,654,259
  • Shares Outstanding, K 322,916
  • Annual Sales, $ 229,210 K
  • Annual Income, $ -116,450 K
  • 60-Month Beta 1.29
  • Price/Sales 24.67
  • Price/Cash Flow N/A
  • Price/Book 43.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.15
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.25 +1.62%
on 03/26/19
23.25 -24.60%
on 03/05/19
-2.48 (-12.39%)
since 02/26/19
3-Month
12.44 +40.92%
on 01/03/19
23.25 -24.60%
on 03/05/19
+3.55 (+25.39%)
since 12/26/18
52-Week
2.35 +645.96%
on 07/31/18
23.33 -24.86%
on 11/06/18
+14.37 (+454.75%)
since 03/26/18

Most Recent Stories

More News
Block & Leviton LLP Reminds Shareholders of Important Deadlines: AMRN, ASTE, INGN, VNDA

Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise acquired...

AMRN : 17.53 (+0.11%)
ASTE : 36.80 (+1.10%)
VNDA : 18.16 (+2.25%)
INGN : 92.64 (+0.94%)
AMRN DEADLINE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Amarin Corporation plc - AMRN

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Amarin Corporation plc (NASDAQ: AMRN) from September 24, 2018 through November 9, 2018,...

AMRN : 17.53 (+0.11%)
Implied Volatility Surging for Amarin (AMRN) Stock Options

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

AMRN : 17.53 (+0.11%)
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KHC, AMRN, WTW and SYNH

The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies...

AMRN : 17.53 (+0.11%)
KHC : 32.90 (+1.23%)
SYNH : 50.50 (+1.24%)
WTW : 20.02 (+1.57%)
Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

Amarin Corporation plc (AMRN)

CVS : 55.39 (+0.80%)
AMRN : 17.53 (+0.11%)
KHC : 32.90 (+1.23%)
CMTA : 25.98 (+0.46%)
OSIR : 19.04 (+0.16%)
LABL : 49.84 (-0.20%)
DPLO : 5.71 (+0.35%)
GTXI : 1.21 (+5.22%)
AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN). The suit is on behalf of investors who purchased or acquired Amarin securities from...

AMRN : 17.53 (+0.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline - AMRN

Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN) and certain of its officers. The class action, filed in United...

AMRN : 17.53 (+0.11%)
APRIL 23 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Amarin Corporation plc - AMRN

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) from September 24, 2018 through November 9,...

AMRN : 17.53 (+0.11%)
Class Action AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC Update

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

AMRN : 17.53 (+0.11%)
CAG : 27.12 (-0.88%)
AKRX : 3.31 (-3.50%)
SHAREHOLDER ALERT: MHLD AMRN INGN USX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

AMRN : 17.53 (+0.11%)
MHLD : 0.74 (-1.17%)
USX : 6.46 (+1.73%)
INGN : 92.64 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AMRN with:

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

2nd Resistance Point 18.09
1st Resistance Point 17.81
Last Price 17.53
1st Support Level 17.25
2nd Support Level 16.97

See More

52-Week High 23.33
Last Price 17.53
Fibonacci 61.8% 15.32
Fibonacci 50% 12.84
Fibonacci 38.2% 10.36
52-Week Low 2.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar